{
 "@context": "https://clearank.com/llms.txt",
 "@type": "clearank:AssetAnalysis",
 "url": "https://clearank.com/stock/teva-pharmaceutical-teva/",
 "dataUrl": "https://clearank.com/stock/teva-pharmaceutical-teva/data.json",
 "title": "Teva Pharmaceutical (TEVA) Stock Forecast (2026)",
 "description": "Teva Pharmaceutical Industries (TEVA) stock forecast 2026: buy, hold or sell? One of the specialty & generic drug manufacturers names we cover.",
 "headline": "Teva Pharmaceutical Industries Ltd. (TEVA)",
 "published": "2026-11-09T18:56:34+00:00",
 "modified": "2026-11-10T23:56:19.264+00:00",
 "generated": "2026-11-11T13:24:38.868Z",
 "language": "en-US",
 "publisher": {
  "name": "CleaRank",
  "url": "https://clearank.com/"
 },
 "disclaimer": "Educational and informational only; not financial advice. AI-generated analysis reviewed by Anthony Beachey, Financial Journalist; prices delayed by up to a minute.",
 "asset": {
  "ticker": "TEVA",
  "name": "Teva Pharmaceutical Industries Ltd.",
  "type": "American Depositary Receipt",
  "exchange": "NYSE",
  "currency": "USD",
  "sector": "Healthcare",
  "industry": "Drug Manufacturers - Specialty & Generic",
  "country": "Israel",
  "website": "https://www.tevapharm.com"
 },
 "quote": {
  "price": 42.4,
  "previousClose": 42.97,
  "change": -0.57,
  "changePercent": -1.33,
  "open": 42.46,
  "high": 42.69,
  "low": 41.65,
  "volume": 6216390,
  "averageVolume": 8023319,
  "marketCap": 49473455641,
  "fiftyTwoWeekHigh": 43.34,
  "fiftyTwoWeekLow": 24.01,
  "marketOpen": false,
  "asOf": "2026-11-10T23:56:19.000Z"
 },
 "statistics": {
  "pe": 98.6,
  "eps": 0.43,
  "dividendYield": 0,
  "beta": 0.842,
  "priceToSales": 2.8714,
  "priceToBook": 6.2840014,
  "revenueTtm": 17230000128,
  "grossMargin": 0.5197971994205698,
  "returnOnEquity": 0.066539995
 },
 "technicals": {
  "rsi": 59.84,
  "macd": 0.7652,
  "sma50": 39.76,
  "sma200": 34.94,
  "rsiSignal": "Neutral",
  "trend": "Bullish",
  "pricePosition": "Bullish",
  "macdSignal": "Bullish",
  "rating": "Bullish"
 },
 "analysis": {
  "rating": "Buy",
  "score": 60,
  "consensus": "Buy",
  "fairValue": null,
  "analystTarget": 48.5,
  "analystCount": 15,
  "wallStreetConsensus": "Buy",
  "generatedAt": "2026-11-10T23:56:19.000Z",
  "priceAtAnalysis": 42.4,
  "volatility": {
   "daily": 1.66,
   "risk": "standard"
  }
 },
 "projections": {
  "basis": "Monte Carlo simulation on historical return distribution, re-run daily; not price targets",
  "years": [
   {
    "year": 2027,
    "downside10th": 23.92,
    "base": 43.89,
    "upside90th": 80.53
   },
   {
    "year": 2028,
    "downside10th": 19.26,
    "base": 45.44,
    "upside90th": 107.2
   },
   {
    "year": 2029,
    "downside10th": 16.44,
    "base": 47.03,
    "upside90th": 134.58
   },
   {
    "year": 2030,
    "downside10th": 14.46,
    "base": 48.69,
    "upside90th": 163.92
   }
  ]
 },
 "faqCount": 5,
 "atAGlance": {
  "asOf": "November 10, 2026",
  "rating": "Buy",
  "score": 60,
  "evidence": [
   {
    "label": "Trend",
    "text": "Up: the price is above both its 50- and 200-day moving averages ($39.76 and $34.94)."
   },
   {
    "label": "Insiders",
    "text": "Insiders sold $76.1M and bought $21K over the last 18 months."
   },
   {
    "label": "Valuation",
    "text": "P/E of 98.6 against 31.9 for the Healthcare sector: a premium to peers (+209%)."
   }
  ]
 },
 "figures": {
  "asOf": "November 10, 2026",
  "earningsReaction": null,
  "insiders": {
   "windowMonths": 18,
   "soldValue": 76101246,
   "boughtValue": 20988,
   "sales": 26,
   "purchases": 1,
   "note": "open-market transactions only; grants and option exercises excluded"
  },
  "drawdown": {
   "years": 10,
   "worstFallPercent": -82.12,
   "peak": "December 2016",
   "trough": "August 2019",
   "recoveredBy": "February 2026",
   "recoveryMonths": 78,
   "belowThatPeakNowPercent": null,
   "fromHighNowPercent": -1.33,
   "oneYearHoldsPositivePercent": 54,
   "dividendsReinvested": false
  },
  "seasonality": {
   "years": 10,
   "bestMonth": {
    "month": "Nov",
    "averagePercent": 11.42,
    "upYearsPercent": 78
   },
   "worstMonth": {
    "month": "Mar",
    "averagePercent": -5.34,
    "upYearsPercent": 30
   }
  },
  "correlations": null,
  "analystTargets": {
   "analysts": 15,
   "low": 42,
   "median": 48.5,
   "high": 57,
   "mean": 49.08,
   "buy": 13,
   "hold": 2,
   "sell": 0
  },
  "dividend": null,
  "simulation": {
   "year": 2030,
   "base": 48.69,
   "percentile10": 14.46,
   "percentile90": 163.92,
   "note": "Monte Carlo simulation outcomes, not price targets"
  }
 },
 "sources": [
  "TwelveData",
  "Wall Street consensus"
 ],
 "sections": [
  {
   "id": "ch-overview",
   "title": "TEVA stock today, November 11, 2026: price, news and analyst targets",
   "text": [
    "As of November 10, 2026, Teva Pharmaceutical Industries Ltd. (TEVA) trades at $42.40. Wall Street's median 12-month price target is $48.50 across 15 analysts, 14.4% above the price. CleaRank rates it Buy with a score of 60/100.",
    "Teva Pharmaceutical Industries Ltd. is trading near the top of its 52-week range, at $42.40 and 2.17% below its 52-week high of $43.34. The stock has risen 74.77% over the past year, and it sits 6.64% above its 50-day average and 21.35% above its 200-day average. Analysts remain positive, with 13 of 15 rating it Buy and a median 12-month target of $48.50.",
    "Recent analyst activity has been uniformly supportive. Leerink Partners kept its Outperform rating on November 5, 2026. TD Cowen and HC Wainwright & Co. each kept their Buy ratings on November 4, 2026, and HC Wainwright started coverage at Buy on November 2, 2026. Barclays kept its Overweight rating on October 15, 2026, and JP Morgan did the same on October 12, 2026. Of the 15 analysts with a current rating, 13 rate the stock Buy and 2 rate it Hold, with none at Sell. Three months ago the count was 12 Buy out of 12 total ratings, so the consensus has not weakened, though the number of ratings has risen.",
    "The trailing P/E of 98.60 is at a premium to peers and sits 209.1% above the sector median of 31.9. The price-to-sales ratio of 2.87 is 15.6% below the sector median of 3.4, so the premium is tied to earnings rather than sales. Trailing GAAP earnings per share are $0.43, which is a thin base for the price. Analysts expect EPS of $2.06 this year and $3.12 next year, so the valuation depends on those estimates being met.",
    "The net profit margin is 2.94% and return on equity is 6.65%, below the sector median of 7.3%. Debt-to-equity is 2.13. The operating margin of 27.40% is far higher than the net margin, which points to heavy costs below the operating line. The company pays no dividend, so returns to shareholders depend entirely on the share price.",
    "Insiders sold $76.1M of stock over the last 18 months across 26 sales, while one open-market purchase totaling $21K was recorded. Insider sales are often planned in advance or made to cover tax on vesting shares, so the sales carry less signal than the purchase, which is small.",
    "CleaRank score 60/100 (Buy). 14 of 17 checks pass: trend 4 of 4, momentum 3 of 3, valuation and quality 2 of 3, analysts 2 of 3, track record 3 of 4.",
    "Teva Pharmaceutical Industries Ltd. ADR is a global pharmaceutical company focused on the development, production, and sale of medicines. Teva Pharmaceutical Industries Ltd. offers a broad portfolio that includes generic medicines, specialty branded treatments, over-the-counter products, active pharmaceutical ingredients, and contract manufacturing services. Its operations are organized across the United States, Europe, and International Markets, supporting distribution to healthcare systems, pharmacies, and patients in diverse regions."
   ]
  },
  {
   "id": "ch-news",
   "title": "TEVA stock news",
   "text": [
    "November 5, 2026·Leerink Partners",
    "Leerink Partners kept its Outperform rating on November 5, 2026. A reiterated positive rating this close to the current price supports the analyst case for further upside.",
    "November 4, 2026·TD Cowen",
    "TD Cowen kept its Buy rating on November 4, 2026. Another Buy call from a major brokerage reinforces the consensus that sits behind the $48.50 median target.",
    "November 4, 2026·HC Wainwright & Co.",
    "HC Wainwright & Co. kept its Buy rating on November 4, 2026. The firm's repeated Buy stance adds to the weight of positive analyst views.",
    "November 2, 2026·HC Wainwright & Co.",
    "HC Wainwright & Co. started coverage at Buy on November 2, 2026. A new Buy initiation adds a fresh positive voice to the analyst group.",
    "October 15, 2026·Barclays",
    "Barclays kept its Overweight rating on October 15, 2026. The reiterated rating is a steady sign of institutional support, though it does not change the stock's valuation premium."
   ],
   "lists": {
    "items": [
     "Leerink keeps Outperform view November 5, 2026·Leerink Partners Leerink Partners kept its Outperform rating on November 5, 2026. A reiterated positive rating this close to the current price supports the analyst case for further upside.",
     "TD Cowen reaffirms Buy November 4, 2026·TD Cowen TD Cowen kept its Buy rating on November 4, 2026. Another Buy call from a major brokerage reinforces the consensus that sits behind the $48.50 median target.",
     "HC Wainwright reaffirms Buy November 4, 2026·HC Wainwright & Co. HC Wainwright & Co. kept its Buy rating on November 4, 2026. The firm's repeated Buy stance adds to the weight of positive analyst views.",
     "HC Wainwright opens coverage at Buy November 2, 2026·HC Wainwright & Co. HC Wainwright & Co. started coverage at Buy on November 2, 2026. A new Buy initiation adds a fresh positive voice to the analyst group.",
     "Barclays keeps Overweight stance October 15, 2026·Barclays Barclays kept its Overweight rating on October 15, 2026. The reiterated rating is a steady sign of institutional support, though it does not change the stock's valuation premium."
    ]
   }
  },
  {
   "id": "ch-street",
   "title": "TEVA price target 2026",
   "text": [
    "The base case is that the stock keeps its upward trend while it stays above its 50-day and 200-day moving averages ($39.76 and $34.94), with the price moving within its typical daily swing of 1.66%. Analyst support is the main reason for the constructive view: the median target of $48.50 sits 14.4% above the price, and the highest target is $57.00. The stock would be better supported if quarterly revenue returns to growth, since analysts expect revenue to shrink 2.8% this year but EPS to grow 51.2% next year to $3.12. The case weakens if the price closes below the 20-day EMA and 50-day SMA, which would signal that the rally is losing ground, or if the lowest target of $42.00, which is close to the current price, begins to look like a ceiling. Earnings are the key test, because at a P/E of 98.60 the valuation leaves little room for disappointment."
   ],
   "tables": [
    {
     "caption": "Recent analyst rating actions on TEVA",
     "columns": [
      "Date",
      "Firm",
      "Action",
      "Rating"
     ],
     "rows": [
      {
       "label": "Nov 5, 2026",
       "cells": [
        "Leerink Partners",
        "Maintains",
        "Outperform"
       ]
      },
      {
       "label": "Nov 4, 2026",
       "cells": [
        "TD Cowen",
        "Maintains",
        "Buy"
       ]
      },
      {
       "label": "Nov 4, 2026",
       "cells": [
        "HC Wainwright & Co.",
        "Maintains",
        "Buy"
       ]
      },
      {
       "label": "Nov 2, 2026",
       "cells": [
        "HC Wainwright & Co.",
        "Initiates",
        "Buy"
       ]
      },
      {
       "label": "Oct 15, 2026",
       "cells": [
        "Barclays",
        "Maintains",
        "Overweight"
       ]
      },
      {
       "label": "Oct 12, 2026",
       "cells": [
        "JP Morgan",
        "Maintains",
        "Overweight"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "ch-levels",
   "title": "TEVA support and resistance levels",
   "text": [
    "Support sits first at the 20-day EMA of $41.29, which the price has been holding above. Below that is the 50-day SMA at $39.76, which is the next level a fall would meet. The 200-day SMA at $34.94 is the deeper support, and the 52-week low of $24.01 marks the bottom of the range. Resistance is the 52-week high at $43.34, the first level a rise would meet. Beyond that, the analysts' lowest target of $42.00 and median target of $48.50 serve as the forecast markers above the price."
   ],
   "tables": [
    {
     "caption": "TEVA support and resistance levels",
     "columns": [
      "Level",
      "What it is",
      "Price",
      "From the price"
     ],
     "rows": [
      {
       "label": "Resistance 1",
       "cells": [
        "52-week high",
        "$43.34",
        "+2.2%"
       ]
      },
      {
       "label": "Price",
       "cells": [
        "November 10, 2026",
        "$42.40",
        ""
       ]
      },
      {
       "label": "Support 1",
       "cells": [
        "20-day exponential average",
        "$41.29",
        "-2.6%"
       ]
      },
      {
       "label": "Support 2",
       "cells": [
        "50-day moving average",
        "$39.76",
        "-6.2%"
       ]
      },
      {
       "label": "Support 3",
       "cells": [
        "200-day moving average",
        "$34.94",
        "-17.6%"
       ]
      },
      {
       "label": "Support 4",
       "cells": [
        "52-week low",
        "$24.01",
        "-43.4%"
       ]
      }
     ]
    }
   ],
   "lists": {
    "items": [
     "RSI Neutral",
     "SMA cross Bullish",
     "Price vs SMA Bullish",
     "MACD Bullish"
    ]
   }
  },
  {
   "id": "ch-price",
   "title": "TEVA stock price and trading"
  },
  {
   "id": "ch-fundamentals",
   "title": "TEVA fundamentals and valuation",
   "text": [
    "Price to earnings vs sector: TEVA trades at a significant premium to sector peers (+209% against the sector median P/E). Investors are paying more for each dollar of earnings than for the typical stock in the sector.",
    "Return vs XLV: Since May 29, 2025, TEVA has gained 145.1% against a gain of 42.3% for XLV.",
    "Revenue growth: Revenue grew 4.3% in FY2025 to $17.3B, from $16.5B a year earlier.",
    "Profit margin: The net margin was 8.2% in FY2025, up from -11.8% the year before.",
    "Profitable: TEVA earned $1.4B in FY2025."
   ]
  },
  {
   "id": "ch-history",
   "title": "TEVA price history and drawdowns",
   "text": [
    "Against the market: TEVA trailed the S&P 500 over this period: $12,095 against $40,115.",
    "A $10,000 investment in TEVA in December 2016 would be worth about $12,095 today, compared with about $40,115 for the same investment in the S&P 500 benchmark with its dividends reinvested."
   ]
  },
  {
   "id": "ch-scenarios",
   "title": "TEVA stock price prediction 2030",
   "text": [
    "CleaRank's simulation projects a price near $48.69 for TEVA by 2030 in the base case, from $42.40 today (1.1x over 4 years). The 10th-percentile path ends near $14.46. These are outcomes of a Monte Carlo simulation run on TEVA's historical return distribution, not price targets, and they assume no dividends are reinvested."
   ],
   "tables": [
    {
     "caption": "TEVA simulated price paths by year",
     "columns": [
      "Year",
      "10th percentile",
      "Base case",
      "90th percentile",
      "range base today"
     ],
     "rows": [
      {
       "label": "2027",
       "cells": [
        "$23.92",
        "$43.89",
        "$80.53",
        ""
       ]
      },
      {
       "label": "2028",
       "cells": [
        "$19.26",
        "$45.44",
        "$107",
        ""
       ]
      },
      {
       "label": "2029",
       "cells": [
        "$16.44",
        "$47.03",
        "$135",
        ""
       ]
      },
      {
       "label": "2030",
       "cells": [
        "$14.46",
        "$48.69",
        "$164",
        ""
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "ch-insiders",
   "title": "TEVA insider trading",
   "text": [
    "Net insider selling: Insiders bought $21K on the open market and sold $76.1M."
   ],
   "tables": [
    {
     "caption": "Insider transactions in TEVA",
     "columns": [
      "Date",
      "Insider",
      "Type",
      "Shares",
      "Value"
     ],
     "rows": [
      {
       "label": "Sep 18, 2026",
       "cells": [
        "Roberto A. Mignone Director",
        "Sell",
        "367.6K",
        "$14.4M"
       ]
      },
      {
       "label": "Sep 18, 2026",
       "cells": [
        "Brian Savage Officer",
        "Sell",
        "7.3K",
        "$285.2K"
       ]
      },
      {
       "label": "Sep 18, 2026",
       "cells": [
        "Brian Savage Officer",
        "Option",
        "4.5K",
        "$156.3K"
       ]
      },
      {
       "label": "Aug 21, 2026",
       "cells": [
        "Amir Weiss Officer",
        "Sell",
        "9.4K",
        "$355.3K"
       ]
      },
      {
       "label": "Aug 21, 2026",
       "cells": [
        "Amir Weiss Officer",
        "Option",
        "2.5K",
        "$49.0K"
       ]
      },
      {
       "label": "Aug 3, 2026",
       "cells": [
        "Eric A Hughes Officer",
        "Sell",
        "25.6K",
        "$892.1K"
       ]
      },
      {
       "label": "Aug 3, 2026",
       "cells": [
        "Placid Jover Officer",
        "Sell",
        "12.8K",
        "$447.4K"
       ]
      },
      {
       "label": "Aug 3, 2026",
       "cells": [
        "Eric A Hughes Officer",
        "Grant",
        "52.7K",
        "-"
       ]
      },
      {
       "label": "Aug 3, 2026",
       "cells": [
        "Placid Jover Officer",
        "Grant",
        "12.8K",
        "-"
       ]
      },
      {
       "label": "Jun 11, 2026",
       "cells": [
        "Eliyahu Sharon Kalif Chief Financial Officer",
        "Sell",
        "106.6K",
        "$3.6M"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "ch-faq",
   "title": "TEVA stock forecast: questions people ask",
   "text": [
    "How these figures are computed, and where the data comes from: CleaRank methodology."
   ]
  },
  {
   "id": "ch-related",
   "title": "Compare TEVA with similar assets",
   "links": [
    {
     "text": "MDT Medtronic NYSE $101.59 -1.17%",
     "url": "https://clearank.com/stock/medtronic-mdt/"
    },
    {
     "text": "GILD Gilead Sciences Inc. NASDAQ $170.87 +0.92%",
     "url": "https://clearank.com/stock/gilead-sciences-gild/"
    },
    {
     "text": "MRNA Moderna Inc. NASDAQ $250.71 -6.80%",
     "url": "https://clearank.com/stock/moderna-mrna/"
    },
    {
     "text": "OSCR Oscar Health, Inc. NYSE $33.47 +4.14%",
     "url": "https://clearank.com/stock/oscr-stock-analysis/"
    },
    {
     "text": "CAH Cardinal Health, Inc. NYSE $276.79 +0.91%",
     "url": "https://clearank.com/stock/cardinal-health-cah/"
    },
    {
     "text": "AZN AstraZeneca NASDAQ $186.76 -1.39%",
     "url": "https://clearank.com/stock/astrazeneca-azn/"
    },
    {
     "text": "AGL agilon health, Inc. NYSE $113.52 -0.44%",
     "url": "https://clearank.com/stock/agl-stock-analysis/"
    },
    {
     "text": "IDXX IDEXX Laboratories, Inc. NASDAQ $696.64 -1.42%",
     "url": "https://clearank.com/stock/idxx-stock-analysis/"
    },
    {
     "text": "IONQ vs RGTI Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/ionq-vs-rgti/"
    },
    {
     "text": "YUM vs QSR Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/yum-vs-qsr/"
    },
    {
     "text": "HD vs LOW Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/hd-vs-low/"
    }
   ]
  }
 ],
 "faq": [
  {
   "question": "What is the TEVA stock forecast?",
   "answer": "The analysts' median 12-month price target is $48.50, which is 14.4% above the current price of $42.40. The targets range from $42.00 to $57.00 across 15 analysts. The nearest level below the price is the 20-day EMA at $41.29, and the nearest level above it is the 52-week high at $43.34."
  },
  {
   "question": "What is the TEVA price target?",
   "answer": "The median 12-month analyst target is $48.50, with the lowest at $42.00 and the highest at $57.00. The Wall Street consensus rating is Buy, with 13 of 15 analysts rating it buy or strong buy. The price of $42.40 sits below the median target and close to the lowest one."
  },
  {
   "question": "Is TEVA a buy or sell today?",
   "answer": "Analysts rate the stock Buy, with 13 of 15 analysts rating it buy, 2 rating it hold, and none rating it sell. CleaRank rates the stock Buy with a score of 60 out of 100. The trend is up, with the price 6.64% above its 50-day SMA and 21.35% above its 200-day SMA."
  },
  {
   "question": "How has TEVA performed over the past year?",
   "answer": "The stock rose 74.77% over the past year and 18.40% over six months. It is 2.17% below its 52-week high of $43.34 and 76.59% above its 52-week low of $24.01."
  },
  {
   "question": "Why is the P/E ratio so high for TEVA?",
   "answer": "The trailing P/E of 98.60 compares with a sector median of 31.9, because trailing GAAP earnings per share are only $0.43. Analysts expect EPS of $2.06 this year and $3.12 next year, which is why the valuation depends on those estimates."
  }
 ],
 "related": {
  "peopleAlsoWatch": [
   {
    "ticker": "MDT",
    "name": "Medtronic NYSE",
    "price": "$101.59",
    "change": "-1.17%",
    "url": "https://clearank.com/stock/medtronic-mdt/"
   },
   {
    "ticker": "GILD",
    "name": "Gilead Sciences Inc. NASDAQ",
    "price": "$170.87",
    "change": "+0.92%",
    "url": "https://clearank.com/stock/gilead-sciences-gild/"
   },
   {
    "ticker": "MRNA",
    "name": "Moderna Inc. NASDAQ",
    "price": "$250.71",
    "change": "-6.80%",
    "url": "https://clearank.com/stock/moderna-mrna/"
   },
   {
    "ticker": "OSCR",
    "name": "Oscar Health, Inc. NYSE",
    "price": "$33.47",
    "change": "+4.14%",
    "url": "https://clearank.com/stock/oscr-stock-analysis/"
   },
   {
    "ticker": "CAH",
    "name": "Cardinal Health, Inc. NYSE",
    "price": "$276.79",
    "change": "+0.91%",
    "url": "https://clearank.com/stock/cardinal-health-cah/"
   },
   {
    "ticker": "AZN",
    "name": "AstraZeneca NASDAQ",
    "price": "$186.76",
    "change": "-1.39%",
    "url": "https://clearank.com/stock/astrazeneca-azn/"
   },
   {
    "ticker": "AGL",
    "name": "agilon health, Inc. NYSE",
    "price": "$113.52",
    "change": "-0.44%",
    "url": "https://clearank.com/stock/agl-stock-analysis/"
   },
   {
    "ticker": "IDXX",
    "name": "IDEXX Laboratories, Inc. NASDAQ",
    "price": "$696.64",
    "change": "-1.42%",
    "url": "https://clearank.com/stock/idxx-stock-analysis/"
   }
  ],
  "comparisons": [
   {
    "ticker": "IONQ vs RGTI Comparison",
    "name": "",
    "url": "https://clearank.com/compare/ionq-vs-rgti/"
   },
   {
    "ticker": "YUM vs QSR Comparison",
    "name": "",
    "url": "https://clearank.com/compare/yum-vs-qsr/"
   },
   {
    "ticker": "HD vs LOW Comparison",
    "name": "",
    "url": "https://clearank.com/compare/hd-vs-low/"
   }
  ],
  "Newly Tracked": [
   {
    "ticker": "CAH",
    "text": "Cardinal Health, Inc.",
    "url": "https://clearank.com/stock/cardinal-health-cah/"
   },
   {
    "ticker": "BAX",
    "text": "Baxter International Inc.",
    "url": "https://clearank.com/stock/baxter-bax/"
   },
   {
    "ticker": "NVAX",
    "text": "Novavax Inc.",
    "url": "https://clearank.com/stock/novavax-nvax/"
   },
   {
    "ticker": "LUMN",
    "text": "Lumen Technologies, Inc.",
    "url": "https://clearank.com/stock/lumen-technologies-lumn/"
   },
   {
    "ticker": "TSCO",
    "text": "Tractor Supply Company",
    "url": "https://clearank.com/stock/tractor-supply-tsco/"
   }
  ],
  "Top Movers (latest session)": [
   {
    "ticker": "PL",
    "text": "↑ 14.50%",
    "url": "https://clearank.com/stock/planet-labs-pl/"
   },
   {
    "ticker": "AMD",
    "text": "↑ 13.26%",
    "url": "https://clearank.com/stock/advanced-micro-devices-amd/"
   },
   {
    "ticker": "ZEC/USD",
    "text": "↓ 12.04%",
    "url": "https://clearank.com/crypto/zcash-zec-usd/"
   },
   {
    "ticker": "RCAT",
    "text": "↑ 11.39%",
    "url": "https://clearank.com/stock/red-cat-rcat/"
   },
   {
    "ticker": "RKLB",
    "text": "↑ 10.91%",
    "url": "https://clearank.com/stock/rocket-lab-rklb/"
   }
  ],
  "Also in Healthcare": [
   {
    "ticker": "HIMS",
    "text": "Hims & Hers",
    "url": "https://clearank.com/stock/hims-hers-health-hims/"
   },
   {
    "ticker": "TEM",
    "text": "Tempus AI Inc",
    "url": "https://clearank.com/stock/tempus-ai-tem/"
   },
   {
    "ticker": "TLRY",
    "text": "Tilray Brands, Inc.",
    "url": "https://clearank.com/stock/tilray-brands-tlry/"
   },
   {
    "ticker": "TMO",
    "text": "Thermo Fisher",
    "url": "https://clearank.com/stock/tmo-stock-analysis/"
   },
   {
    "ticker": "ZTS",
    "text": "Zoetis Inc.",
    "url": "https://clearank.com/stock/zts-stock-analysis/"
   }
  ]
 },
 "schema": [
  {
   "@context": "https://schema.org",
   "@graph": [
    {
     "@type": "Place",
     "@id": "https://clearank.com/#place",
     "address": {
      "@type": "PostalAddress",
      "streetAddress": "Beni Berman 2",
      "addressLocality": "Netanya",
      "addressRegion": "Center",
      "postalCode": "4249330",
      "addressCountry": "IL"
     }
    },
    {
     "@type": "Organization",
     "@id": "https://clearank.com/#organization",
     "name": "CleaRank",
     "alternateName": [
      "CleaRank Financial AI",
      "CleaRank (Clear Rank)"
     ],
     "url": "https://clearank.com",
     "description": "CleaRank is where retail traders research a trade and practice it before risking money. Its research arm, CleaRank Financial AI, publishes daily analysis and 10-year projections for more than 1,000 stocks, ETFs, cryptocurrencies, forex pairs and commodities; each page is built from licensed market data, carries the date it was last updated and is reviewed under CleaRank's published editorial code. The CLEAR™ Score rates online brokers and prop firms on regulation, fees, platform reliability and verified trader experience. The research is free, and so is the Free plan of its trading workbench; CleaRank is paid for by yearly Pro and Unlimited subscriptions to that workbench, which combines a trading simulator, a trade journal that imports from broker history, an AI coach grounded in the trader's own trades, a portfolio generator, visualizer and backtester, a prop-firm challenge auditor and 22 trading calculators and scanners. It uses no affiliate links and takes no payment from the brokers, prop firms or companies it rates or writes about.",
     "slogan": "Clear data. Honest analysis.",
     "logo": {
      "@type": "ImageObject",
      "@id": "https://clearank.com/#logo",
      "url": "https://clearank.com/media/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg",
      "contentUrl": "https://clearank.com/media/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg",
      "caption": "CleaRank",
      "inLanguage": "en-US",
      "width": "336",
      "height": "153"
     },
     "image": {
      "@id": "https://clearank.com/#logo"
     },
     "sameAs": [
      "https://x.com/CleaRank",
      "https://www.linkedin.com/company/clearank/",
      "https://www.youtube.com/@CleaRank",
      "https://t.me/clearank"
     ],
     "email": "info@clearank.com",
     "contactPoint": [
      {
       "@type": "ContactPoint",
       "contactType": "customer support",
       "email": "info@clearank.com",
       "url": "https://clearank.com/contact/",
       "availableLanguage": "en"
      }
     ],
     "address": {
      "@type": "PostalAddress",
      "streetAddress": "Beni Berman 2",
      "addressLocality": "Netanya",
      "addressRegion": "Center",
      "postalCode": "4249330",
      "addressCountry": "IL"
     },
     "location": {
      "@type": "Place",
      "@id": "https://clearank.com/#place",
      "address": {
       "@type": "PostalAddress",
       "streetAddress": "Beni Berman 2",
       "addressLocality": "Netanya",
       "addressRegion": "Center",
       "postalCode": "4249330",
       "addressCountry": "IL"
      }
     },
     "knowsAbout": [
      "stock analysis",
      "ETF analysis",
      "cryptocurrency analysis",
      "forex trading",
      "trading simulation",
      "trade journaling",
      "position sizing",
      "risk management",
      "prop firm challenges",
      "online broker regulation"
     ],
     "publishingPrinciples": "https://clearank.com/editorial-code/",
     "ethicsPolicy": "https://clearank.com/editorial-code/",
     "ownershipFundingInfo": "https://clearank.com/about-us/",
     "owns": {
      "@type": "SoftwareApplication",
      "@id": "https://clearank.com/#app",
      "name": "CleaRank",
      "url": "https://clearank.com/"
     },
     "founder": {
      "@type": "Person",
      "@id": "https://clearank.com/writer/shaundavidb/#person",
      "name": "Shaun David",
      "url": "https://clearank.com/writer/shaundavidb/"
     }
    },
    {
     "@type": "WebSite",
     "@id": "https://clearank.com/#website",
     "url": "https://clearank.com",
     "name": "CleaRank",
     "publisher": {
      "@id": "https://clearank.com/#organization"
     },
     "inLanguage": "en-US"
    },
    {
     "@type": "ImageObject",
     "@id": "https://clearank.com/og/mi/stock/teva-pharmaceutical-teva.png",
     "url": "https://clearank.com/og/mi/stock/teva-pharmaceutical-teva.png",
     "width": "1200",
     "height": "630",
     "caption": "Teva Pharmaceutical Industries Ltd. (TEVA) analysis by CleaRank",
     "inLanguage": "en-US"
    },
    {
     "@type": "BreadcrumbList",
     "@id": "https://clearank.com/stock/teva-pharmaceutical-teva/#breadcrumb",
     "itemListElement": [
      {
       "@type": "ListItem",
       "position": 1,
       "item": {
        "@id": "https://clearank.com",
        "name": "Home"
       }
      },
      {
       "@type": "ListItem",
       "position": 2,
       "item": {
        "@id": "https://clearank.com/stock/",
        "name": "Stocks"
       }
      },
      {
       "@type": "ListItem",
       "position": 3,
       "item": {
        "@id": "https://clearank.com/stock/teva-pharmaceutical-teva/",
        "name": "Teva Pharmaceutical Industries Ltd. (TEVA)"
       }
      }
     ]
    },
    {
     "@type": "WebPage",
     "@id": "https://clearank.com/stock/teva-pharmaceutical-teva/#webpage",
     "url": "https://clearank.com/stock/teva-pharmaceutical-teva/",
     "name": "Teva Pharmaceutical (TEVA) Stock Forecast (2026)",
     "datePublished": "2026-11-09T18:56:34+00:00",
     "dateModified": "2026-11-10T23:56:19+00:00",
     "isPartOf": {
      "@id": "https://clearank.com/#website"
     },
     "primaryImageOfPage": {
      "@id": "https://clearank.com/og/mi/stock/teva-pharmaceutical-teva.png"
     },
     "inLanguage": "en-US",
     "breadcrumb": {
      "@id": "https://clearank.com/stock/teva-pharmaceutical-teva/#breadcrumb"
     },
     "reviewedBy": {
      "@id": "https://clearank.com/writer/anthony-beachey/#person"
     }
    },
    {
     "@type": "Person",
     "@id": "https://clearank.com/writer/anthony-beachey/#person",
     "name": "Anthony Beachey",
     "jobTitle": "Financial Journalist",
     "url": "https://clearank.com/writer/anthony-beachey/",
     "worksFor": {
      "@id": "https://clearank.com/#organization"
     }
    },
    {
     "@type": "Article",
     "@id": "https://clearank.com/stock/teva-pharmaceutical-teva/#richSnippet",
     "headline": "Teva Pharmaceutical (TEVA) Stock Forecast (2026)",
     "name": "Teva Pharmaceutical (TEVA) Stock Forecast (2026)",
     "description": "Teva Pharmaceutical Industries (TEVA) stock forecast 2026: buy, hold or sell? One of the specialty & generic drug manufacturers names we cover.",
     "datePublished": "2026-11-09T18:56:34+00:00",
     "dateModified": "2026-11-10T23:56:19+00:00",
     "author": {
      "@id": "https://clearank.com/#organization"
     },
     "publisher": {
      "@id": "https://clearank.com/#organization"
     },
     "publishingPrinciples": "https://clearank.com/market-insights/methodology/",
     "about": {
      "@type": "Corporation",
      "name": "Teva Pharmaceutical Industries Ltd.",
      "identifier": [
       {
        "@type": "PropertyValue",
        "propertyID": "tickerSymbol",
        "value": "TEVA"
       },
       {
        "@type": "PropertyValue",
        "propertyID": "exchange",
        "value": "NYSE"
       }
      ],
      "description": "Teva Pharmaceutical Industries Ltd. ADR is a global pharmaceutical company focused on the development, production, and sale of medicines. Teva Pharmaceutical Industries Ltd.",
      "tickerSymbol": "TEVA",
      "sameAs": "https://www.tevapharm.com"
     },
     "isPartOf": {
      "@id": "https://clearank.com/stock/teva-pharmaceutical-teva/#webpage"
     },
     "image": {
      "@type": "ImageObject",
      "url": "https://clearank.com/og/mi/stock/teva-pharmaceutical-teva.png",
      "width": 1200,
      "height": 630
     },
     "inLanguage": "en-US",
     "mainEntityOfPage": {
      "@id": "https://clearank.com/stock/teva-pharmaceutical-teva/#webpage"
     }
    }
   ]
  },
  {
   "@context": "https://schema.org",
   "@type": "FAQPage",
   "mainEntity": [
    {
     "@type": "Question",
     "name": "What is the TEVA stock forecast?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "The analysts' median 12-month price target is $48.50, which is 14.4% above the current price of $42.40. The targets range from $42.00 to $57.00 across 15 analysts. The nearest level below the price is the 20-day EMA at $41.29, and the nearest level above it is the 52-week high at $43.34."
     }
    },
    {
     "@type": "Question",
     "name": "What is the TEVA price target?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "The median 12-month analyst target is $48.50, with the lowest at $42.00 and the highest at $57.00. The Wall Street consensus rating is Buy, with 13 of 15 analysts rating it buy or strong buy. The price of $42.40 sits below the median target and close to the lowest one."
     }
    },
    {
     "@type": "Question",
     "name": "Is TEVA a buy or sell today?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Analysts rate the stock Buy, with 13 of 15 analysts rating it buy, 2 rating it hold, and none rating it sell. CleaRank rates the stock Buy with a score of 60 out of 100. The trend is up, with the price 6.64% above its 50-day SMA and 21.35% above its 200-day SMA."
     }
    },
    {
     "@type": "Question",
     "name": "How has TEVA performed over the past year?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "The stock rose 74.77% over the past year and 18.40% over six months. It is 2.17% below its 52-week high of $43.34 and 76.59% above its 52-week low of $24.01."
     }
    },
    {
     "@type": "Question",
     "name": "Why is the P/E ratio so high for TEVA?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "The trailing P/E of 98.60 compares with a sector median of 31.9, because trailing GAAP earnings per share are only $0.43. Analysts expect EPS of $2.06 this year and $3.12 next year, which is why the valuation depends on those estimates."
     }
    }
   ]
  }
 ]
}